Articles by Cynthia Challener, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Cynthia Challener, PhD

Synthetic Biology Stirs Interest in Greener, More Efficient Processes

The commercial availability of an increasing diversity of enzymes has led to the growing use of biocatalysts for API synthesis.
Apr 1, 2014

The commercial availability of an increasing diversity of enzymes has led to the growing use of biocatalysts for API synthesis.

Synthetic Biology: The Next Frontier in Chiral Chemistry for API Synthesis

The commercial availability of an increasing diversity of enzymes has led to the growing use of biocatalysts for API synthesis.
Mar 2, 2014

The commercial availability of an increasing diversity of enzymes has led to the growing use of biocatalysts for API synthesis.

Regulatory Initiatives Spur API Supply Chain Security

Several recent regulatory initiatives designed to secure the global pharmaceutical supply chain have been implemented or are in the process of being adopted.
Feb 28, 2014

In order to ensure a safe drug supply chain, governments have implemented both legislated and voluntary programs designed to address problem areas.

Demand Increases for Novel Excipients, but Manufacturers Still Face Challenges

Feb 28, 2014

Drug formulators are looking for new excipients to address solubility and bioavailability issues and extend patent protection, but there are hurdles to using novel, specialized ingredients.

Securing the Global API Supply Chain

Several recent regulatory initiatives designed to secure the global pharmaceutical supply chain have been implemented or are in the process of being adopted.
Feb 2, 2014

Recent regulatory initiatives designed to secure the global pharmaceutical supply chain will directly impact the global supply chain and API manufacturers.

Advances in UPLC Techniques and Column Chemistry Aid the Confirmation of Biosimilarity

Automated sample handling, advanced glycan analysis and specially designed columns are helping biosimilar manufacturers speed up confirmation of the biosimilarity of their products.
Feb 2, 2014

Automated sample handling, advanced glycan analysis, and specially designed columns are help speed up confirmation of the biosimilarity.

More Rapid Extractable & Leachable Analyses with Advanced Mass Spectrometers

Advances in technology are improving the sensitivity and accuracy of mass spectrometry increasing its use for the analysis of extractables and leachables.
Feb 2, 2014

Advances in technology are improving the sensitivity and accuracy of mass spectrometry, increasing its use for the analysis of extractables and leachables.

Advanced triple quadrupole technology for improved performance and ease of use

Advanced triple quadrupole technology for improved performance and ease of use.
Feb 2, 2014

Advanced triple quadrupole technology for improved performance and ease of use.

Simple and affordable mass detection for the chromatographer

Simple and affordable mass detection for the chromatographer.
Feb 2, 2014

Simple and affordable mass detection for the chromatographer.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
FindPharma Custom Search
Click here